EUCTR2004-003829-28-GB进行中（未招募）1 期
An open-label investigation into the tolerability and pharmacokinetic / pharmacodynamic effects of sufugolix (TAK-013), at a dosage of 100mg twice-daily, during six months treatment of pre-menopausal women with endometriosis.
Takeda Europe R&D Centre Ltd0 个研究点目标入组 0 人开始时间: 2005年2月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Pre-menopausal females aged between 18 and 45 years inclusive.
- •2. New diagnosis of symptomatic endometriosis, or recorded confirmation / re-confirmation by laparoscopy within the 3 years prior to study enrolment. Subjects should have one or more current symptoms comprising dysmenorrhea, pelvic pain, dyspareunia.
- •3. Body Mass Index (BMI) <40 kg/m2.
- •4. Normal menses - defined as three or more consecutive days of bleeding which requires protection, and a cycle duration of 21 - 35 days for at least two menstrual cycles prior to study screening.
- •5. Neither pregnant nor lactating - with negative urine pregnancy tests at study screening and at enrolment (prior to receiving the first dose of study medication).
- •6. Acceptable method of contraception during the entire study duration - defined as use of either a condom plus spermicide preparation, condom plus cap (with or without spermicide) or diaphragm plus condom (with or without spermicide);
- •[Note Unacceptable contraception methods include: oral contraceptive pills or other hormonal methods, IUDs, natural rhythm” methods, withdrawal and spermicides, condoms, caps or diaphragms used alone.]
- •7. With the exception of endometriosis, the subject should otherwise be in good health, with no clinically relevant hepatic, renal, cardiovascular, endocrine, metabolic, psychiatric, neurological, hematological disease, or any other significant illness or clinical condition.
- •8. Ability to comprehend, and willingness to sign, an Informed Consent Form.
- •9. Ability and willingness to undertake all study-related procedures - including the taking of oral medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of any form of cancer (other than adequately treated basal cell and squamous cell cancers of the skin).
- •2. Known to be HIV positive, Hepatitis B surface antigen (HBsAg) or Hepatitis C (HCV) positive.
- •3. ALT/SGPT >1.5 times ULN, bilirubin >1.5 mg/dL, any hepatic or renal impairment.
- •4. Hysterectomy and/or bilateral oophorectomy.
- •5. Abnormal menstrual bleeding unrelated to endometriosis.
- •6. History of osteoporosis, osteopenia, hypocalcemia or other metabolic bone disease.
- •7. Known or documented history of severe allergic or idiosyncratic reactions to any drug – including sufugolix (TAK-013).
- •8. Known history of drug abuse (defined as illicit drug use) or a history of alcohol abuse within the 2 years prior to study enrolment.
- •9. Use of the following medications in the 3 months prior to study enrolment and throughout the study: GnRH analogues, oral contraceptives, sex hormone medications (including - but not limited to - norethindrone or norethindrone acetate, depomedroxyprogesterone, estrogen preparations, other progestins) and Danazol. Investigators should consider any history or prior use of GnRH analogue therapy in terms of possible bone mineral density loss, and take account of such effects in establishing suitability of subjects for this study. (section 7.10 also lists other concomitant medications prohibited throughout the course of this study.)
- •10. A positive pregnancy test.
- •11. Less than 3 months post-partum or post-lactation at onset of therapy within this study.
- •12. Surgery (other than laparoscopy for endometriosis) planned to occur during the 8 months which follow study screening.
- •13. Current participation in any clinical trial (marketed product or otherwise) or within the 30 days prior to the study screening.
- •14. Any disease or disease state that, in the opinion of an investigator, would interfere with the study (e.g. chronic depression requiring treatment).
研究者
相似试验
进行中（未招募）
不适用
An open-label investigation into the tolerability and pharmacokinetic / pharmacodynamic effects of sufugolix (TAK-013), at a dosage of 100mg twice-daily, during six months treatment of pre-menopausal women with endometriosis.symptomatic endometriosisMedDRA version: 7Level: LLTClassification code 10014778EUCTR2004-003829-28-DETakeda Europe R&D Centre Ltd20
进行中（未招募）
1 期
Cysteamine in Cystic FibrosisCystic FibrosisEUCTR2014-000284-40-GBniversity of Aberdeen12
进行中（未招募）
1 期
An open-label study to investigate the tolerability, pharmacokinetics and anti-tumor effect following photodynamic therapy (PDT) with single-ascending doses of LUZ11 in patients with advanced head and neck cancer.EUCTR2013-003133-14-PTuzitin, S.A.6
进行中（未招募）
1 期
Study to evaluate the tolerability of a combination therapy consisting of GAD-alum (Diamyd®), etanercept and vitamin D in children and adolescents newly diagnosed with type 1 diabetesewly diagnosed Type 1 diabetes (within 100 days)MedDRA version: 17.1 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-001323-76-SEinköping University20
进行中（未招募）
1 期
A Clinical Study to evaluate the Safety, Tolerability, and the effects of VX-970 on its own and in combination with Carboplatin on the body in Subjects with Advanced Solid TumorsEUCTR2013-005100-34-GBVertex Pharmaceuticals Incorporated70